OTSU Pharmaceuticals: Major
Health Technology
Mkt Cap
4.6B
P/E (TTM)
13.11
EPS
2.29
ROE
38.45%
Div Yield
—
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 3.78B | 3.16B | 3.05B | 2.85B | 2.55B | |
| Cost of Goods Sold | -2.95B | -2.60B | -2.41B | -1.96B | -1.74B | |
| Gross Profit | 833.27M | 559.16M | 645.83M | 893.58M | 807.29M | |
| SG&A Expenses | -634.88M | -578.45M | -486.72M | -472.91M | -370.79M | |
| Depreciation | -82.58M | -100.34M | -97.92M | -99.82M | -96.04M | |
| Other Operating Expense | 57.68M | 11.60M | 2.48M | 7.17M | -9.46M | |
| Total Operating Expense | -3.52B | -3.17B | -2.89B | -2.42B | -2.12B | |
| Operating Income (EBIT) | 256.07M | -7.69M | 161.59M | 427.83M | 427.04M | |
| Interest Income | 8.05M | 24.23M | 15.48M | 0 | 0 | |
| Interest Expense | -9.00M | -106.17M | -64.42M | -8.14M | -19.78M | |
| Equity in Earnings | 0 | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | -147.59M | 107.94M | -125.89M | -56.57M | 67.62M | |
| Total Non-Operating Income | -148.53M | 26.01M | -174.83M | -63.21M | 42.50M | |
| Pre-Tax Income | 107.54M | 18.32M | -13.24M | 364.63M | 469.54M | |
| Income Tax | -79.86M | -23.09M | 6.04M | -132.83M | -83.20M | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |
| Net Income | 27.68M | -4.76M | -7.21M | 231.80M | 386.33M | |
| EBITDA | 338.97M | 92.98M | 260.30M | 528.57M | 523.85M | |
| EPS (Basic) | 2.29 | -0.39 | -0.60 | 19.16 | 31.93 | |
| EPS (Diluted) | 2.29 | -0.39 | -0.60 | 19.16 | 31.93 | |
| Gross Margin | 22.05% | 17.68% | 21.17% | 31.33% | 31.70% | |
| Operating Margin | 6.78% | -0.24% | 5.30% | 15.00% | 16.77% | |
| EBITDA Margin | 8.97% | 2.94% | 8.53% | 18.53% | 20.57% | |
| Pre-Tax Margin | 2.85% | 0.58% | -0.43% | 12.79% | 18.44% | |
| Net Margin | 0.73% | -0.15% | -0.24% | 8.13% | 15.17% |